Compare Incyte Corporation (INCY) vs Oracle Corporation (ORCL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Oracle Corporation — how do they compare? Incyte Corporation trades at $120.46 (market cap $24.48B), while Oracle Corporation trades at $153.28 (market cap $441.52B). The key difference: Oracle Corporation is far larger — about 18× Incyte Corporation's market cap, and Oracle Corporation pays a 1.3% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | ORCL | |
|---|---|---|
Market Cap | $24.48B | $441.52B |
Sector | Health | Technology |
52-Week High | $129.93 | $328.33 |
52-Week Low | $81.66 | $114.99 |
Enterprise Value | $19.98B | $570.77B |
Dividend Yield | — | 1.3% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Incyte Corporation (INCY) trades at $120.79, down 0.63% today, but maintains a bullish technical trend with strong fundamental performance. The stock is near its 52-week high, supported by robust earnings beats in Q1 and Q2 2026, with revenue growth accelerating to $5.14 billion in 2025. Recent news highlights regulatory approvals for Opzelura in the EU and a raised 2026 revenue outlook following a favorable CMS settlement.
The outlook remains positive given strong analyst consensus (52% buy ratings) and a $122.82 price target, though risks include reliance on key products and competitive pressures. Earnings momentum and institutional accumulation suggest further upside, but investors should monitor execution on growth initiatives.
Oracle Corporation (ORCL) trades at $145.45, down 3.7% today, as the stock faces technical bearish pressure despite strong fundamental performance. The company has consistently beaten earnings expectations in recent quarters with Q1 2026 EPS of $2.11 versus $1.96 expected, while revenue growth accelerated to $57.4 billion in 2025. Analyst sentiment remains overwhelmingly positive with 65% buy ratings and a $252.44 consensus price target, though technical indicators show bearish momentum with RSI levels above 70 suggesting overbought conditions.
Oracle presents a compelling investment case driven by AI infrastructure expansion and consistent earnings beats, but faces near-term technical headwinds and high valuation multiples. The stock's 39.9% May surge reflects AI optimism, though current levels require careful risk management given the bearish technical setup and elevated P/E ratio of 24.95.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Oracle Corporation
Oracle provides database technology and enterprise resource planning, or ERP, software to enterprises around the world. Founded in 1977, Oracle pioneered the first commercial SQL-based relational database management system. Today, Oracle has 430,000 customers in 175 countries, supported by its base of 136,000 employees.
Read more on ORCL →
